Anthropic's AI, Claude, now writes 80% of the company's code, sparking discussions on AI's potential to replace traditional engineering roles and its impact on work culture.

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...

This JetBlue fare is as basic as it gets, but holding Mosaic status could mitigate its toughest restrictions. Want to get somewhere for cheap? Basic economy fares promise to do just that, unbundling ...

Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

PCWorld reports that Spotify offers a hidden “Basic” tier launched in mid-2024 for $10.99/month, providing music-only streaming without audiobooks or lossless audio. This plan requires existing ...

American Airlines will stopped awarding AAdvantage miles and Loyalty Points for basic economy tickets. This policy change aligns American with similar restrictions already in place at other carriers.

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX +3.86%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...